CG Oncology (CGON) EV/EBIT: History & Chart

CG Oncology Inc.(CGON)

Biotechnology · Dallas, TX

$63.90-4.81 (-7.01%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About CG Oncology Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Dallas, TX

142 employees

cgoncology.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Arthur Kuan

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
CG Oncology Inc. (CGON)	$5.64B	N/A	N/A	N/A	N/A
RadNet, Inc. (RDNT)vs ›	$5.54B	77.01x	86.80x	66.21x	59.67x
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.50B	314.54x	339.84x	339.84x	339.84x
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.78B	55.96x	100.68x	164.20x	127.24x
Kodiak Sciences Inc. (KOD)vs ›	$5.82B	N/A	N/A	N/A	N/A
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.90B	59.74x	129.47x	397.21x	199.00x
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.91B	N/A	N/A	N/A	N/A
PTC Therapeutics, Inc. (PTCT)vs ›	$5.32B	42.74x	18.27x	13.52x	13.52x
Doximity, Inc. (DOCS)vs ›	$5.27B	25.79x	27.68x	39.35x	54.79x
GRAIL Inc. (GRAL)vs ›	$6.02B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

CG Oncology Inc. (CGON)

$5.64B

N/A

RadNet, Inc. (RDNT)vs ›

$5.54B

77.01x

86.80x

66.21x